Proto Labs Files 8-K on Financials
Ticker: PRLB · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1443669
| Field | Detail |
|---|---|
| Company | Proto Labs Inc (PRLB) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $100 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, sec-filing
Related Tickers: PRLB
TL;DR
PRLB filed an 8-K on Feb 7th detailing financial results and operations.
AI Summary
Proto Labs, Inc. filed an 8-K on February 7, 2025, reporting on its results of operations and financial condition. The filing also included Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Minnesota and its principal executive offices are located at 5540 Pioneer Creek Drive, Maple Plain, MN.
Why It Matters
This filing provides crucial updates on Proto Labs' financial performance and operational status, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on financial condition and operations, with no immediate indication of significant new risks.
Key Numbers
- 001-35435 — SEC File Number (Identifies the company's filing with the SEC.)
- 41-1939628 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Proto Labs, Inc. (company) — Registrant
- February 7, 2025 (date) — Date of earliest event reported
- Minnesota (location) — State of incorporation
- 5540 Pioneer Creek Drive, Maple Plain, Minnesota 55359 (address) — Principal executive offices
- (763) 479-3680 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.
Are there any new material events disclosed in this filing?
The filing mentions 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' but the specific content of these disclosures is not detailed in the provided text.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on Proto Labs, Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements/exhibits.
When was this 8-K filed?
This 8-K was filed on February 7, 2025.
Where are Proto Labs, Inc.'s principal executive offices located?
Proto Labs, Inc.'s principal executive offices are located at 5540 Pioneer Creek Drive, Maple Plain, Minnesota 55359.
Filing Stats: 659 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-02-07 06:08:18
Key Financial Figures
- $0.001 — ich registered Common Stock, Par Value $0.001 Per Share PRLB New York Stock Exchange
- $100 million — ases, at an aggregate purchase price of $100 million (the "Stock Repurchase Program"). The
Filing Documents
- prlb-20250207.htm (8-K) — 30KB
- prlb-2025207xexx991.htm (EX-99.1) — 419KB
- logo.jpg (GRAPHIC) — 7KB
- logo1.jpg (GRAPHIC) — 2KB
- 0001628280-25-004333.txt ( ) — 608KB
- prlb-20250207.xsd (EX-101.SCH) — 2KB
- prlb-20250207_lab.xml (EX-101.LAB) — 21KB
- prlb-20250207_pre.xml (EX-101.PRE) — 12KB
- prlb-20250207_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 7, 2025, Proto Labs, Inc. (the "Company") issued a press release announcing its fourth quarter and full year 2024 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On February 7, 2025, the Company announced that its board of directors authorized the repurchase of shares of the Company's common stock from time to time on the open market or in privately negotiated purchases, at an aggregate purchase price of $100 million (the "Stock Repurchase Program"). The actual timing, manner, number, and value of shares repurchased under the Stock Repurchase Program will be determined by management at its discretion and will depend on several factors, including the market price of the Company's common stock, general market and economic conditions, applicable requirements, and other business considerations. The Stock Repurchase Program does not obligate the Company to acquire any particular amount of shares of the Company's common stock and remains in effect until the total authorized amount is expended or until further action by the Company's board of directors. The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release of Proto Labs, Inc. dated February 7 , 20 25 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Proto Labs, Inc. Date: February 7, 2025 By: /s/ Daniel Schumacher Daniel Schumacher Chief Financial Officer